The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Meyers-Squibb; Daiichi Sankyo; Lilly; Merck KGaA; Merck Serono; Novartis; Pfizer; Roche
Research Funding - Merck/Pfizer (Inst)
 
Anica Högner
No Relationships to Disclose
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pfizer; Roche Pharma AG; Sanofi; SERVIER
Travel, Accommodations, Expenses - SERVIER
 
Michael Stahl
Honoraria - Bristol-Myers Squibb; Lilly; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD
 
Albrecht Kretzschmar
Honoraria - Amgen; Aspen Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Medac; Merck Serono; MSD; Roche Pharma AG; Sanofi; SERVIER; Shire
Consulting or Advisory Role - Amgen; Roche Pharma AG; Shire
Travel, Accommodations, Expenses - Ipsen; Medac; Merck Serono; PharmaMar
 
Bärbel Schädlich
No Relationships to Disclose
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Gertraud Stocker
Consulting or Advisory Role - Bristol-Myers Squibb; SERVIER
 
Peter Reichardt
Honoraria - Clinigen Group (Inst); Deciphera (Inst); Lilly (Inst); PharmaMar (Inst)
Consulting or Advisory Role - Bayer (Inst); Blueprint Medicines (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
 
Frank Kullmann
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Celgene; MSD Oncology; Novartis; Pierre Fabre
Research Funding - Celgene
 
Daniel Pink
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
 
Prisca Bartels
No Relationships to Disclose
 
Alexej Ballhausen
No Relationships to Disclose
 
Armin Jarosch
No Relationships to Disclose
 
Axel Hinke
Honoraria - Ipsen; Roche Pharma AG
 
Mascha Binder
Honoraria - Abbvie; Amgen; Gilead Sciences; GlaxoSmithKline; Janssen; Merck Serono; MSD; Roche; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; GlaxoSmithKline; Janssen; Merck Serono; MSD; Roche; Sanofi
Research Funding - Ultimovacs (Inst)
 
Alexander Stein
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck KGaA; MSD; Roche; SERVIER
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck KGaA; Roche; Sanofi; Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche